U.S. phase III trial of AZD-1222 for COVID-19 meets primary efficacy endpoint at interim analysis March 22, 2021
Dyadic plans to conduct first-in-human study of its SARS-CoV-2-S-RBD vaccine candidate, DYAI-100 March 22, 2021
FDA clears initiation of phase I study of Meissa's COVID-19 vaccine candidate MV-014-212 March 18, 2021
RSS